Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

• Published in: The New England journal of medicine Vol. 390; no. 4; pp. 301 - 313
• Main Authors: Sonneveld, Pieter, Dimopoulos, Meletios A., Boccadoro, Mario, Quach, Hang, Ho, P. Joy, Beksac, Meral, Hulin, Cyrille, Antonioli, Elisabetta, Leleu, Xavier, Mangiacavalli, Silvia, Perrot, Aurore, Cavo, Michele, Belotti, Angelo, Broijl, Annemiek, Gay, Francesca, Mina, Roberto, Nijhof, Inger S., van de Donk, Niels W.C.J., Katodritou, Eirini, Schjesvold, Fredrik, Sureda Balari, Anna, Rosiñol, Laura, Delforge, Michel, Roeloffzen, Wilfried, Silzle, Tobias, Vangsted, Annette, Einsele, Hermann, Spencer, Andrew, Hajek, Roman, Jurczyszyn, Artur, Lonergan, Sarah, Ahmadi, Tahamtan, Liu, Yanfang, Wang, Jianping, Vieyra, Diego, van Brummelen, Emilie M.J., Vanquickelberghe, Veronique, Sitthi-Amorn, Anna, de Boer, Carla J., Carson, Robin, Rodriguez-Otero, Paula, Bladé, Joan, Moreau, Philippe
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 25.01.2024
• Subjects: Adverse events; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone marrow; Bortezomib; Bortezomib - administration & dosage; Bortezomib - adverse effects; Cancer therapies; CD38 antigen; Death; Dexamethasone; Dexamethasone - administration & dosage; Dexamethasone - adverse effects; Disease Progression; Hematology; Humans; Immunotherapy; Induction therapy; Inhibitor drugs; Lenalidomide - administration & dosage; Lenalidomide - adverse effects; Leukemia; Lymphoma; Minimal residual disease; Monoclonal antibodies; Multiple myeloma; Multiple Myeloma - drug therapy; Neutropenia; Oncology; Risk assessment; Survival; Targeted cancer therapy; Thrombocytopenia; Transplantation; Treatments in Oncology
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2312054

The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy had a significant benefit on progression-free survival among patients with multiple myeloma.